Updated on 27 May 2013
Inex Innovations Exchange (Inex), BGI Clinical Laboratories expand their iGeneScreen test to include the detection of fetal sex chromosome abnormalities
Singapore: Inex Innovations Exchange (Inex), a women's health diagnostics company based in Singapore, and BGI Clinical Laboratories, are expanding their Non Invasive Prenatal Test (NIPT) iGeneScreen to include the detection of fetal sex chromosome abnormalities.
iGeneScreen currently detects Down's syndrome (trisomy 21 or T21), Edward's syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13) with more than 99 percent accuracy.
The expanded service for fetal sex chromosome abnormalities includes the detection for Turner syndrome (Monosomy X), Klinefelter syndrome (XXY), Triple X (XXX) and Jacobs syndrome (XYY), the most common fetal sex chromosome abnormalities.
"We are delighted to offer physicians the option to include sex chromosome aneuploidies, such as Turner and Klinefelter syndromes," said Dr Sidney Yee, chief scientific director, Inex.
"With this expanded service, physicians will be able to have access to more comprehensive analysis for the benefit of their patients, aiding in early management and treatment," she added.